Interview with Cornelia Yzer , CEO, VFA
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
Address: Georg-Glock-Straße 8, 40474 Düsseldorf,Germany
Tel: 0211 – 5 86 01-00
Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of therapeutic, corrective and aesthetic solutions in dermatology. Its expertise spans a broad spectrum of skin, hair and nail diseases. Founded in 1981, Galderma is a joint venture between Nestlé and L’Oréal and employs close to 3.000 people. The company, headed by President & CEO Humberto C. Antunes, has wholly-owned affiliates in 31 countries and a worldwide network of exclusive sales agents. The parent company is based in Lausanne, Switzerland, with Corporate Services in Paris-La Défense, France. In 2008, sales reached 854 million euros, an increase of + 22.4%* over 2007.To drive sustained growth, Galderma invests around 20 percent of revenues in innovation for the development of drugs and other medical solutions which are sourced internally from its own research activities or from partnerships. The R&D staff operates out of 3 specialized sites in the USA, France and Japan.With products sold in more than 65 countries and promoted by a sales force of around 1.000 representatives, Galderma is providing a wide range of innovative medical solutions meeting the highest standards of safety and efficacy. Committed to the future of dermatology, Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meetings the needs of dermatology patients and physicians.
2007 was a turning point for the German Pharmaceutical Industry as the Healthcare Reform from 2007 took place and the Special SHI enhancement Act entered into force. Two years down…
What role does the German Pharmaceutical Industry Association (BPI) play for the German pharmaceutical industry? BPI is the oldest industry association of the German pharmaceutical industry, dating back to 1951.…
Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you…
In the last twenty years, Germany has experienced nearly twenty health care reforms. In your opinion, what have been the main reasons for so many changes? The main reason behind…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
See our Cookie Privacy Policy Here